Loading clinical trials...
Loading clinical trials...
Prostate cancer is the second most common cause of cancer death in men worldwide. After exhausting guideline-compliant therapies or in accordance with the approval of 177Lu-PSMA-617 (Pluvicto®), patie...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Wuerzburg University Hospital
Collaborators
NCT06787053 · Bladder (Urothelial, Transitional Cell) Cancer, Prostate Cancer
NCT07580196 · Prostate Cancer
NCT06616155 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, and more
NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more
NCT07181122 · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
University hospital Wuerzburg - Department of Nuclear Medicine
Augsburg
TUM Klinikum rechts der Isar - Department of Nuclear medicine
München
University hospital Wuerzburg - Department of Nuclear Medicine
Würzburg
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions